Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

INSPIRIS Kina PMCF-studie (INSPIRIS China)

29. september 2026 oppdatert av: Edwards Lifesciences

Post-markeds klinisk oppfølgingsstudie av Edwards Lifesciences INSPIRIS RESILIA aortaklaff i kinesisk befolkning

The objective of this post-market trial is to evaluate long term safety and performance of the Edwards Lifesciences INSPIRIS RESILIA aortic valve in Chinese patients in a real-world clinical setting.

Studieoversikt

Status

Aktiv, ikke rekrutterende

Detaljert beskrivelse

The trial is a multi-center, prospective, single-arm study that will implant up to 250 subjects with the Edwards INSPIRIS RESILIA aortic valve and will continue to follow and assess them after implant for 5 years. In an effort to obtain sufficient long-term data, all subjects will be asked to reconsent to extended follow-up through 10 years.

Studietype

Observasjonsmessig

Registrering (Faktiske)

255

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • Beijing Municipality
      • Beijing, Beijing Municipality, Kina, 100037
        • Fuwai Hospital, CAMS & PUMC
      • Beijing, Beijing Municipality, Kina, 100029
        • Beijing Anzhen Hospital, Capital Medical University
    • Fujian
      • Xiamen, Fujian, Kina, 361008
        • Xiamen Cardiovascular Hospital Xiamen University
    • Guangdong
      • Guangzhou, Guangdong, Kina, 510080
        • The First Affiliated Hospital, Sun Yat-sen University
      • Shenzhen, Guangdong, Kina, 518038
        • Fuwai Hospital Chinese Academy of Medical Sciences, Shenzhen
    • Henan
      • Zhengzhou, Henan, Kina, 450052
        • The First Affiliated Hospital of Zhengzhou University
      • Zhengzhou, Henan, Kina, 450008
        • Henan Provincial Chest Hospital
      • Zhengzhou, Henan, Kina, 451460
        • Fuwai Central China Cardiovascular Hospital
    • Jiangsu
      • Nanjing, Jiangsu, Kina, 210012
        • Nanjing First Hospital
    • Shaanxi
      • Xi'an, Shaanxi, Kina, 710065
        • The First Affiliated Hospital of Xi'an Jiaotong University
    • Sichuan
      • Chengdu, Sichuan, Kina, 610072
        • Sichuan Academy of Medical Sciences·Sichuan Provincial People's Hospital
    • Yunnan
      • Kunming, Yunnan, Kina, 650102
        • Fuwai Yunnan Cardiovascular Hospital

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Prøvetakingsmetode

Ikke-sannsynlighetsprøve

Studiepopulasjon

Subjects requiring an elective replacement of their native or prosthetic aortic valve who have agreed to participate in the study.

Beskrivelse

Inclusion Criteria:

  1. Subject is 18 years or older
  2. Subjects requiring an elective replacement of their native or prosthetic aortic valve as indicated per the IFU
  3. Subject is scheduled to undergo planned aortic valve replacement with or without concomitant coronary bypass surgery, with or without ascending aorta replacement
  4. Provide signed informed consent prior to the study participation

Exclusion Criteria:

  1. Valve implantation is contraindicated per the IFU
  2. Requires planned multiple valve replacement/ repair
  3. Has active endocarditis/myocarditis prior to the scheduled aortic replacement surgery
  4. Estimated Life expectancy< 12 months
  5. Current or recent participation (within 6 weeks prior to surgery) in another drug or device trial

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Observasjonsmodeller: COHORT
  • Tidsperspektiver: PROSPECTIVE

Kohorter og intervensjoner

Gruppe / Kohort
Intervensjon / Behandling
EDWARDS INSPIRIS RESILIA Aortic Valve

Subjects who were treated with the INSPIRIS RESILIA aortic heart valve.

Surgical replacement of the aortic valve with the INSPIRIS RESILIA Aortic Valve.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Subject's Occurrence Rate of Study Valve Related Death
Tidsramme: 10 Years

The primary safety endpoint is the percentage of study valve related death which includes death caused by structural valve deterioration, nonstructural dysfunction, valve thrombosis, embolism, bleeding event, or operated valve endocarditis; death related to reintervention on the operated valve; or sudden, unexplained death.

10 Years
Subject's Occurrence Rate of Structural Valve Deterioration
Tidsramme: 10 Years

The primary safety endpoint is the percentage of Structural Valve Deterioration which includes dysfunction or deterioration involving the operated valve (exclusive of infection or thrombosis), as determined by re-operation, autopsy, or clinical investigation.

10 Years
Subject's Occurrence Rate of Re-operation on the Study Valve
Tidsramme: 10 Years

The primary safety endpoint is the reoperation rate on the study valve which is any operation that repairs, alters, or replaces the study valve, which occurs after the completion of the procedure and the transfer out of the procedure room.

10 Years
Subject's Occurrence Rate of Major Bleeding
Tidsramme: 10 Years

The primary safety endpoint is the rate of major bleeding which is any episode of major internal or external bleeding that causes death, hospitalization, or permanent injury (e.g. Vision loss) or necessitates transfusion of 3 or more units of PRBC, pericardiocentesis, or exploration/reoperation for bleeding.

10 Years
Subject's Occurrence Rate of Thromboembolic Events
Tidsramme: 10 Years

The primary safety endpoint is the rate of thromboembolic events which is an embolic event that occurs in absence of infection (endocarditis) starting from anesthesia time. Embolism may be manifested by a neurologic event (Stroke or Transient Ischemic Attack) or a non-cerebral embolic event.

10 Years
Subject's Occurrence Rate of Stroke
Tidsramme: 10 Years

The primary safety endpoint is the rate of strokes which is a prolonged (>72 hours) or permanent neurologic deficit that is usually associated with abnormal results of magnetic resonance imaging or computed tomographic scans.

10 Years
Subject's Occurrence Rate of Transient Ischemic Attack
Tidsramme: 10 Years

The primary safety endpoint is the rate of transient ischemic attacks which is characterized by fully reversible symptoms of short duration.

10 Years
Subject's Occurrence Rate of Non-Cerebral Thromboembolism
Tidsramme: 10 Years

The primary safety endpoint is the rate of non-cerebral thromboembolism which is an embolus documented operatively, at autopsy, or clinically that produces signs or symptoms attributable to complete or partial obstruction of a peripheral artery (does not include deep vein thrombosis).

10 Years

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Subject's Average Mean Gradient at 10 Years
Tidsramme: 10 Years

Hemodynamic performance - Mean gradients as evaluated by echocardiography

10 Years
Subject's Average Peak Gradient at 10 Years
Tidsramme: 10 Years

Hemodynamic performance - Peak gradients as evaluated by echocardiography

10 Years
Subject's Average Effective Orifice Area at 10 Years
Tidsramme: 10 Years

Hemodynamic performance - Effective Orifice Area evaluated by echocardiography

10 Years
Subject's Average Effective Orifice Area Index at 10 Years
Tidsramme: 10 Years

Hemodynamic performance - Effective Orifice Area Index evaluated by echocardiography

10 Years
Amount of Aortic Central Regurgitation in Subjects at 10 Years
Tidsramme: 10 Years

Hemodynamic performance - Aortic central regurgitation evaluated by echocardiography

10 Years
Amount of Aortic Paravalvular Regurgitation in Subjects at 10 Years
Tidsramme: 10 Years

Hemodynamic performance - Aortic paravalvular regurgitation evaluated by echocardiography

10 Years

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Hansong Sun, Professor, Chinese Academy of Medical Sciences, Fuwai Hospital

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

13. juli 2022

Primær fullføring (Antatt)

1. mars 2034

Studiet fullført (Antatt)

1. desember 2034

Datoer for studieregistrering

Først innsendt

31. mai 2022

Først innsendt som oppfylte QC-kriteriene

31. mai 2022

Først lagt ut (Faktiske)

3. juni 2022

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

2. oktober 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

29. september 2026

Sist bekreftet

1. september 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • 2021-09

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

IPD-planbeskrivelse

Individual participant data will not be available to other researchers.

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Ja

produkt produsert i og eksportert fra USA

Ja

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere